INSM INSMED Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INSM

Price (delayed)

$106.92

Market cap

$23.18B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.74

Enterprise value

$23.34B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 24

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved ...

Highlights
The company's gross profit has surged by 130% YoY and by 39% QoQ
INSM's revenue has surged by 115% year-on-year and by 35% since the previous quarter
The company's quick ratio fell by 26% YoY but it rose by 16% QoQ
INSMED's net income has decreased by 17% YoY but it has increased by 7% QoQ
The equity is down by 4.6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.insmed.com
Peers: SRPT GILD ARRY NVS

Key stats

What are the main financial stats of INSM

INSM stock price

How has the INSMED stock price performed over time
Intraday
-0.46%
1 week
-1.29%
1 month
3.34%
1 year
3.28%
YTD
-38.57%
QTD
0.28%

Financial performance

How have INSMED's revenue and profit performed over time
Revenue
$819.56M
Gross profit
$670.48M
Operating income
-$1.2B
Net income
-$1.18B
Gross margin
81.8%
Net margin
-144.4%
The company's gross profit has surged by 130% YoY and by 39% QoQ
INSM's revenue has surged by 115% year-on-year and by 35% since the previous quarter
The net margin has grown by 46% YoY and by 31% from the previous quarter
INSMED's operating margin has increased by 42% YoY and by 29% from the previous quarter

Price vs fundamentals

How does INSM's price correlate with its fundamentals

Growth

What is INSMED's growth rate over time

Valuation

What is INSMED stock price valuation
P/E
N/A
P/B
32.7
P/S
28.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.47
The EPS has grown by 11% since the previous quarter and by 3.2% year-on-year
The price to book (P/B) is 11% lower than the last 4 quarters average of 36.8
The equity is down by 4.6% from the previous quarter
INSM's revenue has surged by 115% year-on-year and by 35% since the previous quarter
INSM's price to sales (P/S) is 48% lower than its last 4 quarters average of 54.0 but 9% higher than its 5-year quarterly average of 25.9

Efficiency

How efficient is INSMED business performance
INSM's ROE has soared by 71% YoY and by 23% from the previous quarter
The ROS has grown by 45% year-on-year and by 32% since the previous quarter
The ROIC has declined by 37% year-on-year
The company's return on assets rose by 10% QoQ and by 2.1% YoY

Dividends

What is INSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INSM.

Financial health

How did INSMED financials performed over time
INSM's total assets is 51% higher than its total liabilities
The company's quick ratio fell by 26% YoY but it rose by 16% QoQ
The current ratio has contracted by 24% YoY but it has grown by 17% from the previous quarter
The debt is 5% more than the equity
The debt to equity has plunged by 92% YoY but it is up by 4% from the previous quarter
The debt has contracted by 43% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.